IFA testing, or indirect fluorescent antibody testing, is a laboratory method that detects specific antibodies in your blood. It works by making those antibodies visible under a fluorescent microscope, helping doctors identify autoimmune diseases, infections, and other conditions where your immune system produces a measurable response. It’s most commonly encountered as the gold standard method for antinuclear antibody (ANA) screening, which checks for autoimmune disorders like lupus.
How IFA Testing Works
The test starts with a blood draw. Your serum (the liquid part of blood, minus the cells) is placed onto a glass slide that’s been prepared with a known target, such as a layer of specific cells or a particular pathogen. If your blood contains antibodies against that target, they latch on and stick to the slide. Everything else gets washed away.
Next, a second antibody is added. This one is tagged with a fluorescent dye and designed to bind to human antibodies. It essentially lights up wherever your antibodies have attached. A technician then examines the slide under a fluorescence microscope, looking for glowing patterns that indicate a positive result. The brightness and pattern of that glow tell the lab both how many antibodies are present and what type of immune response is occurring.
Because the test uses two layers of antibodies (yours, then the fluorescent-tagged one), it’s called “indirect.” This two-step design makes it sensitive enough to pick up low levels of antibodies that simpler tests might miss.
What IFA Testing Is Used For
The most widespread use of IFA is ANA testing, which screens for autoimmune conditions. When your immune system mistakenly attacks your own cells, it produces antinuclear antibodies that target the nuclei of healthy cells. An IFA test on a special cell line called HEp-2 can detect these antibodies and is used to help evaluate lupus (SLE), rheumatoid arthritis, scleroderma, Sjögren’s syndrome, and mixed connective tissue disease.
Beyond autoimmune screening, IFA is used in infectious disease diagnosis. Labs use the same basic technique to detect antibodies against rabies virus, tick-borne infections, parasitic diseases like leishmaniasis, and other pathogens. In each case, the slide is prepared with the specific organism in question, and the test checks whether your blood carries antibodies against it.
Understanding Titers and Results
IFA results are reported as a titer, which is a measure of how much your blood can be diluted before the antibodies become undetectable. A titer of 1:80, for example, means your serum was diluted 80-fold and still showed a positive signal. Higher titers generally indicate more antibodies.
For ANA testing, a titer of 1:80 or greater on HEp-2 cells is widely considered significant. The joint 2019 guidelines from the American College of Rheumatology and the European League Against Rheumatism set a positive ANA at 1:80 or higher as a required entry criterion for classifying lupus. For autoimmune hepatitis, titers of 1:80 and 1:160 are used as diagnostic thresholds depending on the method. Lower dilutions like 1:10 or 1:20 are more likely to reflect background noise rather than true disease.
A positive result alone doesn’t mean you have an autoimmune disease. Positive ANA screens are not unusual in elderly people or those with certain infections like mononucleosis. Your doctor interprets the titer alongside your symptoms, medical history, and other lab work.
What Staining Patterns Reveal
When the ANA IFA test comes back positive, the lab also reports the staining pattern, which describes where the fluorescence appears on the cells. Different patterns point toward different conditions.
- Homogeneous: The entire nucleus glows uniformly. This is the pattern most frequently associated with lupus.
- Speckled (fine or coarse): The nucleus shows scattered dots of fluorescence. A fine speckled pattern is more common in Sjögren’s syndrome, while coarse speckled patterns can appear in other connective tissue diseases.
- Nucleolar: Only the structures inside the nucleus that produce proteins light up. This pattern is sometimes linked to scleroderma.
- Centromere: Distinct, evenly spaced dots appear across the nucleus. This pattern is associated with a limited form of scleroderma.
Research in pediatric rheumatology patients has confirmed that homogeneous patterns and higher titers cluster together in diseases most strongly associated with ANA, with the majority of those patients ultimately diagnosed with lupus. The pattern gives your doctor a starting point for ordering more targeted follow-up tests.
IFA Compared to Other Testing Methods
The American College of Rheumatology designated IFA on HEp-2 cells as the gold standard for ANA testing in a 2009 position statement. That status has loosened slightly. Updated 2019 guidelines now allow laboratories to use newer automated methods, such as solid-phase immunoassays (sometimes called ELISA-based tests), provided they can demonstrate equivalent performance.
In direct comparisons for detecting lupus, IFA and ELISA show the same sensitivity at about 78%. Where they diverge is specificity: ELISA correctly rules out lupus about 81% of the time, compared to roughly 59% for IFA. That means IFA is somewhat more likely to produce a false positive. When the comparison broadens to include all autoimmune diseases, IFA picks up slightly more true positives (81% sensitivity versus 78% for ELISA) but still trails in specificity (64% versus 79%).
The tradeoff is that IFA provides staining pattern information that automated assays cannot. That pattern data can be clinically valuable, especially early in a diagnostic workup when the specific disease isn’t yet clear.
Limitations of IFA Testing
The biggest drawback of IFA is subjectivity. A technician manually dilutes your serum, processes the slides, and reads the results through a microscope. Two different technicians can sometimes disagree on the exact titer or the staining pattern, particularly at borderline dilutions. This makes the test less reproducible than fully automated alternatives.
The manual nature also limits how many samples a lab can process at once, which can affect turnaround time. Results typically come back within one to four days, though this varies by laboratory and how many additional tests are ordered alongside it.
A negative ANA by IFA doesn’t always rule out autoimmune disease. If the test comes back negative but symptoms strongly suggest lupus or Sjögren’s syndrome, doctors may order specific antibody tests (such as anti-Ro/SSA) that can catch cases the ANA screen misses.
What to Expect as a Patient
IFA requires a standard blood draw, no different from routine lab work. If the blood sample is only being used for ANA testing, no fasting is needed. If your doctor is running additional tests on the same sample, you may be asked to fast beforehand. Certain medications can affect the accuracy of the results, so bring a list of everything you take to your appointment.
After the draw, there’s nothing else you need to do. Results are interpreted by your doctor in the context of your full clinical picture. A single positive ANA doesn’t lock you into a diagnosis, and a single negative result doesn’t guarantee you’re in the clear. Most often, IFA is one piece of a larger diagnostic puzzle.